NeoGenomics, Inc. (NEO) Q2 FY26 Earnings Call

$201.7 million revenue grew 11%, clinical revenue grew 14%, and 2026 adjusted EBITDA guidance rose to $56-$58 million.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-28
Length60 minutes
EPS$-0.01
Revenue$186.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All NEO earnings ยท Back to NEO overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.